spacer
home > ebr > winter 2002 > from genes to drugs
PUBLICATIONS
European Biopharmaceutical Review

From Genes to Drugs

One of the biggest obstacles in the development of cancer therapeutics is the sheer complexity of the problem. Cancer may result from a large number of genetic and molecular defects, or combination of these defects, giving rise to loss of cell cycle checkpoints and unregulated cell division. Even individual tumours may exhibit heterogeneous phenotypes at the cellular level. The inherent genetic instability of cancer cells may also add to the problem, enabling them to continue to change during treatment and effectively presenting a moving target.The majority of anti-cancer therapeutics currently in use were discovered due to their ability to kill fast-growing cancer cells. Unfortunately, these often cause severe side effects due to their impact on other fast-growing cells in the body. There is, therefore, a need to design drugs that target a specific pathogenic pathway and to base the design of the drug upon the structure of its protein target.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Bob Jackson, Executive Director of R&D at Cyclacel Dr Robert Jackson joined Cyclacel in January 2001. Prior to this he was Research and Development Director at Celltech Group plc and Executive Director, R&D and Chief Operating Officer at Chiroscience Group plc.
Before these appointments, Dr Jackson was Vice President of R&D at Agouron Pharmaceuticals and headed cancer research at DuPont Pharmaceuticals and Warner-Lambert Company. Dr Jackson has been instrumental in the discovery and development of several marketed drugs used to treat cancer, HIV and other serious diseases. He holds a BA from the University of Cambridge and a PhD from the University of London, Institute of Cancer Research.

spacer
Dr Bob Jackson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI China opens with analysis pointing to a surge in growth in 2019

Shanghai, 23rd May 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) – co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets – forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement